Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidanc...(see note (e) for details); costs associa...)

early termination of debt/credit facilities (see note (f) for

details); certain other gains or losses that are either isolated or

cannot be expected to occur again with any regularity or

predictability (see note (g) for details); the tax consequences of the

preceding items and other tax events (see note (h) for details); and

results of discontinued operations.

(c) Reported results in 2007 include $49.2 primarily for charges for the

sale of inventories revalued at the date of acquisition. Reported

results in 2006 include $74.8 of charges for the sale of

inventories revalued at the date of acquisition and $2.9 of

accelerated depreciation on manufacturing assets abandoned due to

facility consolidations.

(d) Reported results in 2007 and 2006 include restructuring and other

costs, net, consisting principally of severance, abandoned facility

and other expenses of real estate consolidation and, in 2007,

loss on sale of business, net of net gains in 2006 on the sale of

product lines and abandoned facilities. Reported results in 2006 also

include $15.2 of charges for in-process research and

development associated with the Fisher merger.

(e) Reported results in 2006 include a charge for the acceleration of

equity-based compensation expense due to a change in control.

(f) Reported results in 2006 include $0.9 of cost associated with the

early termination of debt/credit facilities in interest expense.

(g) Reported results in 2007 included an $8.9 loss from an other than

temporary decline in the fair market value of an available-for-sale

investment and a $4.5 currency transaction gain associated with an

intercompany financing transaction.

(h) Reported provision for income tax
'/>"/>